The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
about
ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.Nanotherapeutics for multiple myeloma.Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD Decline
P2860
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@en
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@nl
type
label
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@en
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@nl
prefLabel
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@en
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@nl
P2093
P2860
P1476
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
@en
P2093
Christopher M Terry
Rory M Shallis
Seah H Lim
P2860
P2888
P304
P356
10.1007/S00262-017-1990-2
P577
2017-03-24T00:00:00Z